Sangamo Reports on Third Quarter 2025 Achievements
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a pioneering genomic medicine company headquartered in Richmond, California, has made significant strides in developing innovative therapies for serious medical conditions. With recent achievements reported for the third quarter of 2025, Sangamo is making waves in the field of genomic medicine.
Key Updates from Recent Business Developments
During this quarter, Sangamo has continued to enhance its clinical and pre-clinical pipeline. A notable milestone is the activation of the first two clinical sites in the Phase 1/2 STAND study, focusing on chronic neuropathic pain. Patient recruitment has begun, and the company anticipates dosing the first patient shortly. These advancements represent a critical expansion of Sangamo's neurology programs.
Engagement with Regulatory Bodies
Sangamo recently held a meeting with the U.S. Food and Drug Administration (FDA). In this meeting, the FDA reaffirmed its agreement to incorporate estimated glomerular filtration rate (eGFR) slope as a pivotal endpoint for the accelerated approval pathway for isaralgagene civaparvovec—a novel gene therapy for Fabry disease.
Fabry Disease Treatment Insights
Moreover, Sangamo has presented clinical findings from the registrational STAAR study, highlighting potential benefits of isaralgagene civaparvovec as a durable one-time treatment. Clinical results indicated significant multi-organ clinical benefits, suggesting that this therapeutic approach could effectively address the underlying pathology of Fabry disease and exceed current treatment standards.
Financial Overview for Third Quarter 2025
For the third quarter of 2025, Sangamo reported a net loss of $34.9 million, equivalent to $0.11 per share. This stands in contrast to the net income of $10.7 million, or $0.04 per share, reported for the same period in the previous year. Revenue for Q3 2025 was recorded at $0.6 million, significantly lower than the $49.4 million achieved in Q3 2024, primarily due to reduced collaboration revenue.
Operating Expenses Analysis
Operating expenses on a GAAP basis were $36.1 million, slightly down from $38.8 million in Q3 2024. This decrease can largely be attributed to lower personnel costs, reflecting management's focus on optimizing operational efficiency. Non-GAAP expenses, which indeed exclude non-cash charges, totaled $33.0 million in the third quarter, compared to $34.2 million the previous year.
Pioneering Actions in Neurology and Prion Disease Research
Sangamo continues to demonstrate its commitment to advancing research in neurology. The company’s pipeline includes ST-503 and ST-506, investigational therapies designed for treating chronic neuropathic pain and prion diseases, respectively. With ongoing preparations for a Biologics License Agreement (BLA) submission anticipated in early 2026, Sangamo is poised for evolving its therapeutic offerings.
Upcoming Financial Guidance
Sangamo has reiterated its financial guidance for the fiscal year, with projected total operating expenses ranging between $135 million to $155 million, inclusive of stock-based compensation and depreciation costs. The management team is committed to maintaining a focus on core neurology programs while navigating business development opportunities for potential commercialization agreements.
Sangamo's Commitment to Patients and Innovation
Sangamo Therapeutics remains steadfast in its mission to transform the lives of patients through groundbreaking genomic therapies. The company leverages innovative scientific advancements to target serious neurological diseases, ensuring that the needs of patients are prioritized in the research and development process.
Frequently Asked Questions
1. What are the recent achievements of Sangamo Therapeutics?
Sangamo has activated clinical sites for the STAND study and reported significant advancements in its Fabry disease treatment.
2. What is isaralgagene civaparvovec?
Isaralgagene civaparvovec is a gene therapy aimed at providing a long-lasting treatment for Fabry disease.
3. What were Sangamo's reported financial results for Q3 2025?
The company reported a net loss of $34.9 million and revenues of $0.6 million.
4. How does Sangamo plan to manage its expenses moving forward?
Management plans to focus on operational efficiencies and maintain low gross expenses while advancing their neurology pipeline.
5. When is Sangamo's BLA submission expected?
The company anticipates submitting its Biologics License Agreement in early 2026.
